Cochrane Review Group

Infectious Diseases

135 systematic reviews in Infectious Diseases ask 1,518 questions. 8.9% have no studies to answer them, 23.1% rest on very low certainty evidence and 30.5% reach moderate or high certainty.

Reviews

135

Questions

1,518

current versions

No studies

8.9%

Moderate or high

30.5%

No studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Infectious Diseases

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment All‐cause mortality – at 28 to 30 days, or in‐hospital · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	RR 0.84 [0.49, 1.46]	11 studies · 3459 participants	Very low
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Progression to invasive mechanical ventilation · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	RR 0.86 [0.68, 1.09]	8 studies · 1383 participants	Very low
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Time to clinical improvement (defined as time to a 2‐point reduction in patients’ admission status on WHO’s ordinal scale) · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	HR 1.13 [0.69, 1.83]	4 studies · 721 participants	Very low
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Virologically confirmed dengue case incidence (any severity, any phenotype) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of dengue RNA in the mosquito population · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Mosquito density (for population suppression strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of Wolbachia‐carrying mosquitoes (for population replacement strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Adverse events potentially related to Wolbachia‐carrying Aedes deployments · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR NRCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies